Clinical Trials and Research Roundup | Ivermectin Repurposing for COVID-19: The Israeli Perspective

‘Generic Drug Repurposing for COVID-19” The Israeli Perspective’:
Tel Aviv University’s Spark program recently hosted a webinar titled “Generic Drug Repurposing for COVID-19: The Israeli Perspective.” In collaboration with the MedInsight Institute, presenters included Professor Alex Jadad, Faculty of Medicine and School of Public Health, University of Toronto, Canada; Moshe Rogosnitzky, Executive Director, MedInsight Research Institute from both New York and Israel; professor Yaakov Nahmias, Director for the Center of Bio engineering, the Hebrew University of Jerusalem; and Professor Eli Schwartz with Sheba Medical Center, Tel Aviv University, #Israel, who presented the “Sheba #Ivermectin Project (SIP).” Establishing a movement in Israel to consider the repurposing of generic drugs for purposes of economically and forcefully targeting #COVID-19, the drugs discussed in this presentation included Ivermectin, are potentially safe, effective and widely accessible. The organizers of this event are clear for the world to hear: “Of the 9,000 currently approved drugs that exist globally, the potential for overcoming COVID-19 certainly exists.”
https://trialsitenews.com/generic-drug-repurposing-for-covid-19-the-israeli-perspective/
The FLCCC Alliance press conference from Houston, Texas:
Some Highlights from the press conference starring the Frontline COVID19 Critical Care Alliance from Houston, Texas to discuss emerging evidence for economical and widely available therapeutic possible options for treating early-stage COVID-19 cases.
See the whole press conference here: https://www.youtube.com/watch?v=4V3yxrJwJQs&feature=youtu.be
Great Plains Health Severe COVID-19 Patients Benefit from RLF-100:
Recently showcased on local media, North Platte Nebraska’s Great Plains Health (GPH) has treated at least 20 patients with Aviptadil (RLF-100), an investigational product recently submitted for emergency use authorization in late September. One of those surviving patients, Mark Cardenas, went on air to share his experience and thanks for the access. It literally may have saved his life. Produced by a Swiss company called Relief Therapeutics, Great Plains Health infectious disease physician Eduardo Freitas heard about the drug via a network of other physicians. It was through that network that Dr. Freitas was able to secure a communication channel with U.S and Israel-based NeuroRx, the biotechnology company that co develops the drug for commercialization. TrialSite has reported on a few situations in Texas where patients with severe COVID-19 experienced marked improvement thanks to access to the drug opened up by the U.S. Food and Drug Administration via clinical trials and Expanded Access Protocol. It is through the latter that GPH was able to offer the investigational product to select patients facing severe COVID-19 conditions.
https://trialsitenews.com/great-plains-health-severe-covid-19-patients-benefit-from-rlf-100/

Видео Clinical Trials and Research Roundup | Ivermectin Repurposing for COVID-19: The Israeli Perspective канала TrialSite News